Objective {#Sec1}
=========

Transcription of a eukaryotic protein-coding gene by pol II requires several steps, including transcription initiation, elongation, and termination. During transcription, co-transcriptional processes such as mRNA capping, splicing, and cleavage and polyadenylation also occur and are required for the production of a mature mRNA. The end of a protein-coding gene is defined by one or more poly(A) sites and recognition of a poly(A) site is essential for the cleavage and polyadenylation of the mRNA \[[@CR1], [@CR2]\]. Approximately 85 proteins make up the cleavage and polyadenylation (CPA) complex and are distributed between four multi-subunits complexes that regulate poly(A) site recognition, pre-mRNA cleavage, and polyadenylation \[[@CR2], [@CR3]\]. The four complexes are cleavage and polyadenylation specificity factor (CPSF), cleavage stimulation factor (CstF), and cleavage factors I (CFIm) and II (CFIIm) \[[@CR3]\]. CFIm is composed of two CFIm25 subunits, which binds the pre-mRNA, and two larger subunits, CFIm59 and CFIm68 \[[@CR4], [@CR5]\]. CFIm binds the pre-mRNA 40--50 nt upstream of the poly(A) site but its role in pre-mRNA cleavage remains unclear \[[@CR6]\]. However, previous studies have shown a shift towards proximal poly(A) site usage following depletion of CFIm25 or CFIm68 \[[@CR7]--[@CR9]\], suggesting a role of CFIm in promoting distal poly(A) site recognition and longer mRNA 3′UTRs \[[@CR10]\].

Some proteins of the CPA complex, including CstF64, CPSF73, and the CPA-associated termination factor Xrn2 have been shown to regulate pol II activity at the beginning and end of the transcription cycle \[[@CR11], [@CR12]\]. To determine whether depletion of CFIm also affects pol II pausing and transcription, we used a CRISPR/Cas9 approach to reduce the expression of two subunits of CFIm, CFIm25 and CFIm68 \[[@CR8], [@CR13]\], and performed pol II ChIP-seq in the CFIm68KD cell line in absence or presence of an inhibitor of cyclin-dependent kinase (CDK)9, whose activity regulates pol II pause release and entry into productive elongation \[[@CR14]\].

Data description {#Sec2}
================

Cell culture {#Sec3}
------------

HEK293 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Sigma) supplemented with 10% fetal bovine serum (FBS, Gibco) and 100 units/ml penicillin + 100 µg/ml streptomycin (Gibco). The CFIm68KD cell lines, and its respective control HEK293 Flp, were previously described \[[@CR8]\]. The cell lines were treated prior to ChIP-seq with DMSO or 100 µM 5,6-dichlorobenzimidazone-1-β-[d]{.smallcaps}-ribofuranoside (DRB, Sigma) for 30 min (Table [1](#Tab1){ref-type="table"}).Table 1Overview of data filesLabelName of data file/data setFile types (file extension)Data repository and identifier (DOI or accession number)Data file 1 \[[@CR20], [@CR21]\]293 Flp-In InputFastq.gz (raw files), bigwig (processed files)ENA accession number (fastq.gz): <https://identifiers.org/ena.embl:SRX2915405>GEO accession number (bigwig): <https://identifiers.org/geo:GSM2666454>Data file 2 \[[@CR20], [@CR21]\]293 Flp-In Pol IIFastq.gz (raw files), bigwig (processed files)ENA accession number (fastq.gz): <https://identifiers.org/ena.embl:SRX2915406>GEO accession number (bigwig): <https://identifiers.org/geo:GSM2666455>Data file 3 \[[@CR20], [@CR21]\]293 Flp-In DRB InputFastq.gz (raw files), bigwig (processed files)ENA accession number (fastq.gz): <https://identifiers.org/ena.embl:SRX6095228>GEO accession number (bigwig): <https://identifiers.org/geo:GSM3898200>Data file 4 \[[@CR20], [@CR21]\]293 Flp-In DRB Pol IIFastq.gz (raw files), bigwig (processed files)ENA accession number (fastq.gz): <https://identifiers.org/ena.embl:SRX6095229>GEO accession number (bigwig): <https://identifiers.org/geo:GSM3898201>Data file 5 \[[@CR20], [@CR21]\]68KD InputFastq.gz (raw files), bigwig (processed files)ENA accession number (fastq.gz): <https://identifiers.org/ena.embl:SRX2915407>GEO accession number (bigwig): <https://identifiers.org/geo:GSM2666456>Data file 6 \[[@CR20], [@CR21]\]68KD Pol IIFastq.gz (raw files), bigwig (processed files)ENA accession number (fastq.gz): <https://identifiers.org/ena.embl:SRX2915408>GEO accession number (bigwig): <https://identifiers.org/geo:GSM2666457>Data file 7 \[[@CR20], [@CR21]\]CFIm68KD DRB InputFastq.gz (raw files), bigwig (processed files)ENA accession number (fastq.gz): <https://identifiers.org/ena.embl:SRX6095230>GEO accession number (bigwig): <https://identifiers.org/geo:GSM3898202>Data file 8 \[[@CR20], [@CR21]\]CFIm68KD DRB Pol IIFastq.gz (raw files), bigwig (processed files)ENA accession number (fastq.gz): <https://identifiers.org/ena.embl:SRX6095231>GEO accession number (bigwig): <https://identifiers.org/geo:GSM3898203>Additional file [1](#MOESM1){ref-type="media"} \[[@CR22]\]List of primers.docx10.6084/m9.figshare.9159869Additional file [2](#MOESM2){ref-type="media"} \[[@CR23]\]Pol II ChIP-qPCR results.pdf10.6084/m9.figshare.9159878

ChIP-qPCR and ChIP-seq {#Sec4}
----------------------

ChIP was performed as previously described \[[@CR15]\]. Briefly, cells were crosslinked at room temperature with 1% formaldehyde and quenched with 125 mM glycine for 5 min. Nuclear extracts were sonicated twice on a Bioruptor (Diagenode) for 15 min at high amplitude, 30 s ON/30 s OFF. 80 μg of chromatin was incubated overnight at 4 °C with 2 μg of an antibody against IgG (sc-2027, Santa Cruz) or against pol II (sc-899X, Santa Cruz). After recovery of immune complexes with BSA-saturated protein G Dynabeads and extensive washes, crosslinks were reversed by incubation at 65 °C for 5 h. After ethanol precipitation and proteinase K treatment, DNA was purified using a MinElute PCR Purification Kit (Qiagen). A single replicate of ChIP samples were sequenced on an Illumina HiSeq 4000 with 75 bp paired-end reads (Wellcome Trust Centre for Human Genetics, University of Oxford). For ChIP-qPCR, the list of primers can be found in Additional file [1](#MOESM1){ref-type="media"}. Pol II ChIP-qPCR were done in biological triplicates and can be found in Additional file [2](#MOESM2){ref-type="media"}. Statistical test: unpaired *t* test, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.

Bioinformatics analysis {#Sec5}
-----------------------

Adapters were trimmed with Cutadapt v. 1.9.1 \[[@CR16]\] with the following constant parameters: \--minimum-length 10 --q 15, 10 \--max-n 1. Obtained sequences were mapped to the human hg19 reference sequence with Bowtie2 v. 2.2.5 \[[@CR17]\]. Unmapped reads were removed with SAMtools v. 1.3.1 \[[@CR18]\]. Mapped reads were then de-duplicated using Picard to remove PCR duplicates. Bam files were sorted and indexed with SAMtools. Bigwig files were created with a FPKM (Fragments per kilobase per million mapped reads) normalization by employing deepTools2 v. 2.2.4 \[[@CR19]\] bamCoverage tool with the following parameters: -bs 10 -normalizeToRPKM -e --p max. Metaprofiles were created with deepTools2 computeMatrix tool.

Limitations {#Sec6}
===========

The knockdown of CFIm68 was not complete and may therefore may not be sufficient to completely abrogate the role of CFIm68 in pol II pausing and transcription regulation. The ChIP-seq were performed only once and in only one cell line; HEK293. We also performed pol II ChIP-qPCR on a limited number of protein-coding genes.

Supplementary information
=========================

 {#Sec17}

**Additional file 1.** List of primers, List of primers used for the ChIP-qPCR presented in additional file. **Additional file 2.** Pol II ChIP-qPCR results, results of the pol II ChIP-qPCR on three genes in the HEK293 Flp-In and CFIm68KD cell lines.

Pol II

:   RNA polymerase II

DRB

:   5,6-dichlorobenzimidazone-1-β-[d]{.smallcaps}-ribofuranoside

ChIP

:   chromatin immunoprecipitation

DMEM

:   Dulbecco's Modified Eagle's Medium

FBS

:   fetal bovine serum

FPKM

:   fragments per kilobase per million mapped reads

3′UTR

:   3′ untranslated region

CDK9

:   cyclin-dependent kinase 9

CPA

:   cleavage and polyadenylation complex

CFIm

:   cleavage factor I
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